grail styled grail american biotechnology company menlo park california subsidiary illumina started startup seeking develop early cancer screening test people liquid biopsy also called multicancer early detection launched june called galleri test detects fragments dna blood sample via nextgeneration sequencing identifies dna methylation distinct patterns associated particular cancers potentially allowing early detection cancer providing information origin cancer one three multicancer screening tests investigation two cancerseek assay panseer assay grail began san francisco biotechnology pharmaceutical startup company parent company illumina san diego produces dna sequencing machines scientists use study human biology diagnose rare genetic richard klausner chief medical officer illumina former director national cancer institute advocated new business according san francisco business times correctly predicted dna sequencing technology would make possible detect evidence tumor blood also joined grails board according forbes grails profits kept september illumina announced agreement purchase grail outright november grail announced commercial partnership national health service england nhs trial galleri test reporting march federal trade commission ftc sued block vertical september administrative judge ruled ftcs position antitrust october european commission ordered grail divested illumina within next twelve illuminas research showed repeatedly sequencing dna bloodstream made possible detect floating bits dna cancer cells initially aimed recruit greater people clinical trials order accumulate sizeable data required detect interpret cancer grail calls liquid biopsy early cancer galleri test galleri multicancer early detection mced test one three multicancer screening tests investigation validated november two cancerseek assay panseer galleri test detects fragments dna blood sample via nextgeneration sequencing identifies dna methylation distinct patterns associated particular cancers potentially allowing early detection cancer providing information origin grails first clinical trial galleri test circulating cellfree genome atlas study looked distinctive cancer types blood tumour tissue samples people locations north america including people new cancer blood samples people without cancer subsequently galleri test entered three trials strive summit pathfinder results pathfinder presented september showed positive predictive value detection earlystage cancer test predicting cancer signal origin accuracy less three months galleri received breakthrough device designation us food drug administration may test diagnose rather detects possible signs cancer order help direct followup diagnostic galleri yet approved fda available prescription agencys provision laboratory developed test diagnose rather detects possible signs cancer order help direct followup diagnostic november grail announced commercial partnership national health service england nhs trial galleri several scientists responded nhs england interventional randomised controlled trial includes two groups participants group people aged identified nhs records symptoms yearly blood test three years second group people possible cancer trial started august primary completion date estimated july study completion february june company began selling galleri tests january least seventeen clinical trials progress investigate performance clinical utility multicancer early detection tests six involving june grail disclosed telemedicine vendor pwnhealth mistakenly informed patients may cancer company asserted incident due software configuration issue pwnhealth due incorrect galleri test